TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26238974

Group type: EXPERIMENTAL
Intervention: Achievement of disease targets (SDAI ≤3.3)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Achievement of disease targets (CDAI ≤2.8)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Achievement of disease targets (DAS28-CRP <2.6)
Number of subjects: 1297

Group type: EXPERIMENTAL
Intervention: Achievement of disease targets
Number of subjects: 1297
Study: 26239690

Group type: EXPERIMENTAL
Intervention: Concurrent antipsychotic medications (including 40 mg pimavanserin daily)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Concurrent antipsychotic medications
Number of subjects: 459
Study: 26240075

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (intermittent walking to mild-to-moderate claudication pain for 3 months)
Number of subjects: 46
Study: 26241603

Group type: EXPERIMENTAL
Intervention: Screening for Partner Violence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study: 26241763

Group type: EXPERIMENTAL
Intervention: Moderate to severe CPSP (NRS ≥3/10) at 12 months
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Severe pain (NRS ≥6) at 12 months
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Signs of neuropathic pain in patients with moderate CPSP
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Signs of neuropathic pain in patients with severe CPSP
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Functional impairment (BPI) at 6 and 12 months
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Risk factors for CPSP
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Percentage of time in severe pain on D1
Number of subjects: 3120
Study: 26242184

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA) therapy
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: GLP-1RA therapy
Number of subjects: 620
Study: 26242577

Group type: EXPERIMENTAL
Intervention: Major Depression Inventory (MDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 0
Study: 26242713

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) pre-PCI
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) post-PCI
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Post-PCI FFR values
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACE) at 30 days
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Physician decision-making influenced by OCT
Number of subjects: 418
Study: 26242794

Group type: EXPERIMENTAL
Intervention: Treatment of depression as measured by the Montgomery and Asberg Depression Rating Scale (MADRS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Individual MADRS items during treatment
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Treatment of depression
Number of subjects: 145
Study: 26242981

Group type: COMPARATOR
Intervention: Intravenous adenosine infusion (140-175mcg/kg/min)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Regadenoson bolus (400mcg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Regadenoson single-bolus administration
Number of subjects: 149
Study: 26243227

Group type: EXPERIMENTAL
Intervention: RC-ABC (ABC/2 score calculated at a specialized reading center)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: site-ABC (ABC/2 score calculated at local site)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: RC-ABC
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: ABC/2 scores at local or central sites
Number of subjects: 507
Study: 26243260

Group type: EXPERIMENTAL
Intervention: Acute exacerbations of COPD (AE-COPD)
Number of subjects: 33
Study: 26243788

Group type: EXPERIMENTAL
Intervention: Hypertensive pregnancy
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Normotensive pregnancy
Number of subjects: 2637
Study: 26244136

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0
Study: 26244396

Group type: EXPERIMENTAL
Intervention: Transmitters (n=91)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Nontransmitters (n=91)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study: 26244751

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 0
Study: 26244832

Group type: EXPERIMENTAL
Intervention: Dolutegravir (1.0 mg/kg once daily)
Number of subjects: 23
Study: 26244883

Group type: EXPERIMENTAL
Intervention: Bipolar Patients (BP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy Subjects (HS)
Number of subjects: 27
Study: 26245196

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 10 µL with 2,500 PfSPZ (n=6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 50 µL with 2,500 PfSPZ (n=6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 µL with 2,500 PfSPZ (n=6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 25,000 PfSPZ (n=6)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 75,000 PfSPZ (n=6)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Direct venous inoculation of 3,200 PfSPZ (n=6)
Number of subjects: 36
Study: 26245279

Group type: EXPERIMENTAL
Intervention: Medifast 4 & 2 & 1 Plan
Number of subjects: 310
Study: 26245808

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 9
Study: 26245948

Group type: EXPERIMENTAL
Intervention: Abdominoperineal excision (APE)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Extralevator APE (ELAPE)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: More severe perineal symptoms
Number of subjects: 545
Study: 26246321

Group type: EXPERIMENTAL
Intervention: Caloric restriction (<900 kcal/d) for 6 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caloric restriction (<900 kcal/d) for 12 weeks
Number of subjects: 9
Study: 26246436

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 70
Study: 26246845

Group type: EXPERIMENTAL
Intervention: Grape extract (GE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26246908

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 26248048

Group type: EXPERIMENTAL
Intervention: Clinical predictors associated with HRQoL outcomes
Number of subjects: 256
Study: 26248353

Group type: EXPERIMENTAL
Intervention: 1g meropenem every 8 hours as a 15-min infusion
Number of subjects: 5
Study: 26248495

Group type: EXPERIMENTAL
Intervention: Thigh-high compression stockings
Number of subjects: 47

Group type: COMPARATOR
Intervention: No compression stockings (control)
Number of subjects: 47
Study: 26248638

Group type: EXPERIMENTAL
Intervention: secukinumab 2×10 mg/kg intravenously followed by 3 mg/kg IV every 4 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 26250067

Group type: COMPARATOR
Intervention: Brexpiprazole (2-4 mg/day for schizophrenia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole (for relapse prevention/maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole (1, 2, and 3 mg for MDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole (for schizophrenia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole (for MDD)
Number of subjects: 0
Study: 26250576

Group type: EXPERIMENTAL
Intervention: lenalidomide and rituximab
Number of subjects: 0
Study: 26250700

Group type: EXPERIMENTAL
Intervention: Tracheal intubation attempted in 92% of cases
Number of subjects: 2327

Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices used in 5% of cases
Number of subjects: 2327

Group type: EXPERIMENTAL
Intervention: Bag-valve-mask ventilation used in 2% of cases
Number of subjects: 2327

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure used in 0.2% of cases
Number of subjects: 2327

Group type: COMPARATOR
Intervention: Cardiac arrest patients
Number of subjects: 2327

Group type: COMPARATOR
Intervention: Non-cardiac arrest patients
Number of subjects: 2327
Study: 26251048

Group type: EXPERIMENTAL
Intervention: HIV infected MSM
Number of subjects: 26503

Group type: EXPERIMENTAL
Intervention: HIV infected PWID
Number of subjects: 26503
Study: 26251214

Group type: EXPERIMENTAL
Intervention: Recombinant HCV E1E2 with MF59C.1 adjuvant
Number of subjects: 112

Group type: COMPARATOR
Intervention: Mock treatment with a control peptide
Number of subjects: 112
Study: 26251251

Group type: EXPERIMENTAL
Intervention: SAMMPRIS medical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: WASID treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lack of statin use at enrollment (WASID patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior infarcts in the territory of the symptomatic vessel (WASID patients)
Number of subjects: 0
Study: 26251255

Group type: EXPERIMENTAL
Intervention: Copeptin levels in nonsurviving patients (n=8)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Copeptin levels in surviving patients (n=151)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Comparison of copeptin levels between cerebrovascular and stroke mimic patients
Number of subjects: 561

Group type: COMPARATOR
Intervention: Comparison of copeptin levels between vascular and nonvascular patients
Number of subjects: 561

Group type: COMPARATOR
Intervention: Copeptin levels and time from onset to blood draw
Number of subjects: 561
Study: 26251590

Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EBV) therapy
Number of subjects: 43
Study: 26251605

Group type: EXPERIMENTAL
Intervention: Max%ΔBW > 5%
Number of subjects: 465
Study: 26252393

Group type: EXPERIMENTAL
Intervention: Migalastat HCl (150 mg or 450 mg) co-administered with agalsidase (0.2, 0.5, or 1.0 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Agalsidase (0.2, 0.5, or 1.0 mg/kg) alone
Number of subjects: 23
Study: 26252852

Group type: EXPERIMENTAL
Intervention: Anal insert device
Number of subjects: 91
Study: 26252914

Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL D) patients
Number of subjects: 49
Study: 26253018

Group type: EXPERIMENTAL
Intervention: Automated image analysis using a sequential classification algorithm based on glandular and cellular morphology
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Automated image analysis applied to an independent validation set
Number of subjects: 58
Study: 26253733

Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR) assessment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: FFR for flow-limiting coronary artery disease (FFR≤0.8)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for FFR
Number of subjects: 106
Study: 26254174

Group type: EXPERIMENTAL
Intervention: Unilateral subcapsular orchiectomy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aromatase inhibitor (letrozol, 2.5 mg/d for 3 months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Preoperative testosterone levels
Number of subjects: 14
Study: 26254317

Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment (MAT)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Drug-free counseling
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: NA/AA meetings only
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: No additional treatment
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Residential treatment preference
Number of subjects: 485
Study: 26254445

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 510863

Group type: EXPERIMENTAL
Intervention: Guideline recommended care
Number of subjects: 510863

Group type: EXPERIMENTAL
Intervention: Hospital level variation in treatment
Number of subjects: 510863

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for hospitals' use of PCI
Number of subjects: 510863
Study: 26254472

Group type: EXPERIMENTAL
Intervention: Decision tree for serious infection diagnosis
Number of subjects: 8962
Study: 26254576

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise programme for 6 months (OW-Trained)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: OW-Trained
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: OW-Untrained
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control and OW-Trained
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 19
Study: 26254812

Group type: EXPERIMENTAL
Intervention: MET-HIT2000AB4 sandwich strategy (postoperative chemotherapy, hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy)
Number of subjects: 23

Group type: COMPARATOR
Intervention: HIT'91 maintenance strategy (postoperative craniospinal radiotherapy, and maintenance chemotherapy)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Large cell/anaplastic medulloblastoma
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Classic medulloblastoma
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Desmoplastic medulloblastoma
Number of subjects: 23
Study: 26254836

Group type: EXPERIMENTAL
Intervention: Ultrasound findings categorized as cirrhosis
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Ultrasound findings categorized as homogeneous
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Ultrasound findings categorized as heterogeneous
Number of subjects: 719

Group type: COMPARATOR
Intervention: Ultrasound findings categorized as normal
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Early infection with Pseudomonas aeruginosa (<2 years old)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid use
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: CF-related diabetes
Number of subjects: 719
Study: 26255045

Group type: EXPERIMENTAL
Intervention: Family history of CRC (1 first degree relative)
Number of subjects: 14961

Group type: EXPERIMENTAL
Intervention: Family history of CRC (≥2 first degree relatives)
Number of subjects: 14961

Group type: EXPERIMENTAL
Intervention: Family history of CRC
Number of subjects: 14961
Study: 26257082

Group type: EXPERIMENTAL
Intervention: PreImplantation Factor (PIF)
Number of subjects: 0
Study: 26258315

Group type: EXPERIMENTAL
Intervention: Living donor liver transplant (LDLT)
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Deceased donor liver transplant
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: All recipients
Number of subjects: 1427
Study: 26258656

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Overall (laparoscopic and vaginal)
Number of subjects: 242
Study: 26259955

Group type: EXPERIMENTAL
Intervention: Trametinib (1.0, 2.0, or 3.0 mg once daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trametinib (2.0 mg once daily) in combination with gemcitabine (1000 mg/m(2))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Trametinib monotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Trametinib plus gemcitabine
Number of subjects: 18
Study: 26260007

Group type: EXPERIMENTAL
Intervention: Two-month walking program (one-hour sessions, three times a week)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 9
Study: 26260306

Group type: EXPERIMENTAL
Intervention: HCVIDD/MA
Number of subjects: 53
Study: 26261061

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and oxaliplatin
Number of subjects: 519
Study: 26261238

Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b (50 to 540 µg, administered every 2 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Number of subjects: 51
Study: 26261290

Group type: EXPERIMENTAL
Intervention: Native T1 measurement in hypo-intense infarct core (n = 160 STEMI patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adverse remodelling defined as an increase in left ventricular (LV) end-diastolic volume ≥20% at 6 months
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All-cause death or first heart failure hospitalization
Number of subjects: 300
Study: 26261849

Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with nintedanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 26263403

Group type: EXPERIMENTAL
Intervention: ETR 400 mg plus TDF/FTC 300/200 mg once daily
Number of subjects: 79
Study: 26263832

Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhoids (Goligher grade I-II)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhoids (Goligher grade III)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Symptomatic hemorrhoids (Goligher grade IV)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 97
Study: 26264378

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg daily for 4 weeks of a 6-week cycle (Cohort A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily on a continuous basis (Cohort B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 52
Study: 26264607

Group type: EXPERIMENTAL
Intervention: EMMA™ portable-capnometer
Number of subjects: 35

Group type: COMPARATOR
Intervention: Side stream capnometry
Number of subjects: 35
Study: 26265011

Group type: EXPERIMENTAL
Intervention: Nasal provocation test - rapid (NPT-R)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Classic nasal provocation test (NPT)
Number of subjects: 88
Study: 26265013

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 42
Study: 26265130

Group type: EXPERIMENTAL
Intervention: Preferential routing to approved stroke centers (ASCs)
Number of subjects: 1627
Study: 26265463

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Non-nucleotide reverse transcriptase inhibitor- and integrase-strand inhibitor-based cART
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: cART regimen not altered after HCT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: cART regimen altered due to complications
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Enfuvirtide as bridging component
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: cART adherence
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sustained HIV viremia and emergence of resistance
Number of subjects: 15
Study: 26265479

Group type: EXPERIMENTAL
Intervention: PUR118 5.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PUR118 11.0 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PUR118 2.8 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PUR118 high dose (11.0 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All dosages of PUR118
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ozone challenge
Number of subjects: 24
Study: 26265699

Group type: EXPERIMENTAL
Intervention: SNP rs10989692 (near the glutamate receptor GRIN3A locus)
Number of subjects: 2285

Group type: EXPERIMENTAL
Intervention: SNP rs10989692
Number of subjects: 2285

Group type: EXPERIMENTAL
Intervention: Osteonecrosis-associated glutamate receptor variants
Number of subjects: 2285

Group type: EXPERIMENTAL
Intervention: Glutamate pathway
Number of subjects: 2285
Study: 26266019

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 1
Study: 26266252

Group type: EXPERIMENTAL
Intervention: Nonvoluntary isometric contractions (twitch and tetanic) of the quadriceps femoris muscle evoked by transcutaneous electrical muscle stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonvoluntary isometric contractions (twitch)
Number of subjects: 12
Study: 26266842

Group type: EXPERIMENTAL
Intervention: Abnormal CMAP on day 8
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Abnormal SNAP and presence of SEA on day 15
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Reduced CMAP on day 8
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Reduced CMAP among conscious/cooperative patients without weakness
Number of subjects: 730
Study: 26267622

Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2285

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 2285
Study: 26268313

Group type: EXPERIMENTAL
Intervention: PanAd3-RSV (IM prime)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PanAd3-RSV (IM boost)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MVA-RSV (IM boost)
Number of subjects: 42
Study: 26268514

Group type: EXPERIMENTAL
Intervention: Carnitine (20 mg/kg, IV) prior to IVIR
Number of subjects: 26

Group type: COMPARATOR
Intervention: IVIR (Sodium ferric gluconate, [125 mg/100 ml] for 8 weeks)
Number of subjects: 26
Study: 26268782

Group type: EXPERIMENTAL
Intervention: 60-min rituximab infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard second dose infusion recommendation
Number of subjects: 50
Study: 26268844

Group type: COMPARATOR
Intervention: Healthy/PA cluster (n=265)
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Healthy/diet cluster (n=unknown)
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Unhealthy cluster (n=677)
Number of subjects: 1327
Study: 26269220

Group type: EXPERIMENTAL
Intervention: ZDV-containing ARV regimens
Number of subjects: 12780

Group type: COMPARATOR
Intervention: non-ZDV ARV regimens
Number of subjects: 12780
Study: 26269238

Group type: EXPERIMENTAL
Intervention: Total PUFA intake
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Higher ratio of PUFAs to SFAs
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Intakes of n-3 PUFAs
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Intakes of n-6 PUFAs
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Ratio of n-6 to n-3 PUFAs
Number of subjects: 311
Study: 26269363

Group type: EXPERIMENTAL
Intervention: Hydration status measured through urinary osmolality (Uosm)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Total urine volume (Uvol)
Number of subjects: 78